TD Cowen reaffirmed their hold rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports.
FUSN has been the topic of several other reports. Raymond James reiterated a market perform rating on shares of Fusion Pharmaceuticals in a research note on Tuesday, March 19th. Leerink Partnrs lowered shares of Fusion Pharmaceuticals from an outperform rating to a market perform rating in a research note on Tuesday, March 19th. Wedbush lowered shares of Fusion Pharmaceuticals from an outperform rating to a neutral rating and set a $24.00 target price on the stock. in a research report on Tuesday, March 19th. Brookline Capital Management lowered shares of Fusion Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, March 19th. Finally, Jefferies Financial Group restated a hold rating and set a $21.00 target price (up from $10.00) on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. Thirteen analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of Hold and a consensus target price of $20.25.
View Our Latest Stock Analysis on FUSN
Fusion Pharmaceuticals Stock Performance
Fusion Pharmaceuticals (NASDAQ:FUSN – Get Free Report) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative return on equity of 46.59%. Research analysts forecast that Fusion Pharmaceuticals will post -1.46 EPS for the current fiscal year.
Institutional Investors Weigh In On Fusion Pharmaceuticals
Several hedge funds have recently modified their holdings of FUSN. Perceptive Advisors LLC acquired a new stake in shares of Fusion Pharmaceuticals during the first quarter worth $10,405,000. FMR LLC lifted its holdings in shares of Fusion Pharmaceuticals by 73.9% during the first quarter. FMR LLC now owns 4,681,457 shares of the company’s stock worth $17,649,000 after purchasing an additional 1,989,403 shares during the period. Federated Hermes Inc. lifted its holdings in Fusion Pharmaceuticals by 94.1% in the first quarter. Federated Hermes Inc. now owns 3,055,037 shares of the company’s stock valued at $23,738,000 after acquiring an additional 1,481,037 shares during the period. Sphera Funds Management LTD. acquired a new stake in Fusion Pharmaceuticals in the first quarter valued at $4,839,000. Finally, Wellington Management Group LLP acquired a new stake in Fusion Pharmaceuticals in the fourth quarter valued at $7,154,000. 72.85% of the stock is owned by institutional investors and hedge funds.
Fusion Pharmaceuticals Company Profile
Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.
See Also
- Five stocks we like better than Fusion Pharmaceuticals
- Why is the Ex-Dividend Date Significant to Investors?
- Comprehensive PepsiCo Stock Analysis
- Investing in large cap stocks: Diving into big caps
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Consumer Staples Stocks, Explained
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Fusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.